Lilian Y. Li
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Journal: Cancer chemotherapy and pharmacology
Published: August 23, 2021
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 06, 2021
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
Journal: CPT: pharmacometrics & systems pharmacology
Published: February 26, 2021
The impact of vaccine procurement methods on public health in selected European countries.
Journal: Expert review of vaccines
Published: January 29, 2020
Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Journal: European journal of drug metabolism and pharmacokinetics
Published: November 02, 2019
Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
Journal: Journal of clinical pharmacology
Published: July 11, 2019
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Journal: Journal of clinical pharmacology
Published: July 02, 2019
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: May 10, 2019
Risk assessment of fragility fractures: summary of NICE guidance.
Journal: BMJ (Clinical research ed.)
Published: August 10, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026